Adverum Biotechnologies (ADVM) Expected to Announce Earnings on Monday

Adverum Biotechnologies (NASDAQ:ADVM) is expected to be announcing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($1.80) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 7, 2025 at 9:30 AM ET.

Adverum Biotechnologies (NASDAQ:ADVM) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($2.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.24) by ($0.10). On average, analysts expect Adverum Biotechnologies to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Adverum Biotechnologies Trading Down 2.6%

Adverum Biotechnologies stock opened at $4.07 on Monday. The company has a fifty day simple moving average of $3.84 and a 200-day simple moving average of $3.05. The stock has a market cap of $85.39 million, a P/E ratio of -0.52 and a beta of 0.98. Adverum Biotechnologies has a 12-month low of $1.78 and a 12-month high of $8.21.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Adverum Biotechnologies during the second quarter worth approximately $153,000. Qube Research & Technologies Ltd acquired a new stake in shares of Adverum Biotechnologies in the second quarter valued at approximately $66,000. Marshall Wace LLP purchased a new position in shares of Adverum Biotechnologies during the second quarter worth approximately $107,000. XTX Topco Ltd acquired a new position in shares of Adverum Biotechnologies in the 2nd quarter valued at $64,000. Finally, AQR Capital Management LLC acquired a new position in shares of Adverum Biotechnologies in the 1st quarter valued at $148,000. Hedge funds and other institutional investors own 48.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adverum Biotechnologies in a report on Friday. Chardan Capital reissued a “buy” rating and set a $33.00 target price on shares of Adverum Biotechnologies in a research report on Wednesday, August 13th. Royal Bank Of Canada upgraded Adverum Biotechnologies to a “hold” rating in a research note on Thursday, October 9th. Truist Financial set a $5.00 price target on shares of Adverum Biotechnologies in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Adverum Biotechnologies in a report on Tuesday, September 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $16.80.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.